Last reviewed · How we verify
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.
Details
| Lead sponsor | Juventas Cell Therapy Ltd. |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 100 |
| Start date | Thu Dec 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Dec 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Relapsed or Refractory Acute Lymphoblastic Leukemia
Interventions
- single dose of CNCT19
Countries
China